Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Surveys and Questionnaires 7Interviews as Topic 7Blood Specimen Collection 5Specimen Handling 4Exercise Test 4fludarabine 3Voriconazole 3Mental Status and Dementia Tests 3Bortezomib 3Standard of Care 2Observation 2Itraconazole 2Flow Cytometry 2Electronic Health Records 2Data Collection 2Antiviral Agents 2posaconazole 1liposomal amphotericin B 1isavuconazole 1glucarpidase 1fludarabine phosphate 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Whole-Body Irradiation 1Watchful Waiting 1Vincristine 1Valganciclovir 1Transplantation 1Tomography, X-Ray Computed 1Tomography, Optical Coherence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Hematologic Neoplasms × Glycopeptides × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡